Drug Trial Radar · NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Aug 2027
Study completion Apr 2033
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in virologically suppressed people with HIV-1 (PWH) in treatment Group 1, 2 and 3 at Week 35. In Part B the goal of the study is to compare the effectiveness of switching to the study drugs, GS-3242 and LEN versus continuing B/F/TAF in Groups 4 and 3 at Week 26. The primary objective of part A is to evaluate the efficacy of switching to intramuscular (IM) GS-3242 plus IM LEN versus continuing on B/F/TAF PWH who are virologically suppressed in treatment Groups 1, 2, and 3 at Week 35 and Part B is to evaluate the efficacy of switching to IM GS-3242 plus IM LEN versus continuing on B/F/TAF in PWH who are virologically suppressed in Treatment Groups 4 and 3 at Week 26.
Conditions
- HIV-1-infection
Interventions
GS-3242 TabletDrug
Administered orally
GS-3242 InjectionDrug
Administered intramuscularly (IM)
Lenacapavir TabletDrug
Administered orally
Lenacapavir InjectionDrug
Administered IM
B/F/TAFDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 35
- Part B: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 26
Locations
59 sites in 4 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians
Phoenix, Arizona · Not yet recruiting
Pacific Oak Medical Group
Beverly Hills, California · Recruiting
Ruane Clinical Research Group Inc.
Los Angeles, California · Recruiting
Optimus Medical Group
San Francisco, California · Recruiting
University of California San Francisco, Community and Clinical Research Center
San Francisco, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Recruiting
Mills Clinical Research
West Hollywood, California · Not yet recruiting
University of Colorado Clinical and Translational Research Center
Aurora, Colorado · Not yet recruiting
Vivent Health
Denver, Colorado · Recruiting
Midland Florida Clinical Research Center, LLC
DeLand, Florida · Recruiting
CAN Community Health Fort Lauderdale
Fort Lauderdale, Florida · Recruiting
Midway Immunology and Research Center
Ft. Pierce, Florida · Recruiting
AIDS Healthcare Foundation -Coconut Grove
Miami, Florida · Recruiting
Floridian Clinical Research, LLC
Miami Lakes, Florida · Recruiting
Orlando Immunology Center, PA
Orlanda, Florida · Recruiting
AHF - Pensacola
Pensacola, Florida · Recruiting
CAN Community Health Inc.
Sarasota, Florida · Recruiting
Triple O Research Institute, PA
West Palm Beach, Florida · Recruiting
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia · Recruiting
Metro Infectious Disease Consultants, P.L.L.C.
Decatur, Georgia · Recruiting
Mercer University, Department of Internal Medicine
Macon, Georgia · Recruiting
Chatham County Health Department
Savannah, Georgia · Recruiting
Be Well Medical Center
Berkeley, Michigan · Recruiting
KC CARE Health Center
Kansas City, Missouri · Recruiting
Southampton Community Healthcare
St Louis, Missouri · Recruiting
ID care
Hillsborough, New Jersey · Recruiting
Saint Michael's Medical Center
Newark, New Jersey · Recruiting
South Jersey Infectious Disease
Somers Point, New Jersey · Recruiting
AXCES Research Group, LLC
Sante Fe, New Mexico · Recruiting
Brooklyn Clinical Research
Brooklyn, New York · Recruiting
NewYork-Presbyterian Queens
Flushing, New York · Recruiting
NYU Langone Health Vaccine Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Not yet recruiting
The Brody School of Medicine at East Carolina University
Greenville, North Carolina · Not yet recruiting
Rosedale Health and Wellness
Huntersville, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Not yet recruiting
Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
Philadelphia, Pennsylvania · Recruiting
Central Texas Clinical Research
Austin, Texas · Recruiting
St. Hope Foundation
Bellaire, Texas · Recruiting
Prism Health North Texas
Dallas, Texas · Recruiting
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.